Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Physiol Behav. 2024 Apr 23;281:114565. doi: 10.1016/j.physbeh.2024.114565

Table 2.

Clinical studies of GLP-1R agonists and nicotine use disorder.

Publication/ClinicalTrials.gov ID Clinical population Outcome measures GLP-1R agonist Study length Results/Study status
Lengsfeld et al. [129] 255 smokers 18–75 y/o with at least moderate nicotine dependence
(n = 128 placebo + varenicline, n = 127 dulaglutide + varenicline)		 Smoking abstinence Craving for smoking Body weight change HbA1c levels Dulaglutide (1.5 mg weekly) or placebo in addition to smoking cessation counseling and oral varenicline (2 mg/daily) 12 weeks No effect on abstinence or craving Reduced post-cessation body weight gain Decreased HbA1c levels
Yammine et al. [128] 84 treatment-seeking smokers 18–75 y/o with prediabetes and/or overweight
(n = 41 placebo + NRT, n = 41 exenatide + NRT)		 Smoking abstinence Craving for smoking Self-reported withdrawal Body weight change Extended-release exenatide (2 mg weekly) or placebo in addition to smoking cessation counseling and NRT (21 mg/daily) 6 weeks Increased abstinence Decreased craving Decreased withdrawal Reduced post-cessation body weight gain
NCT03712098 40 treatment-seeking smokers 18 y/o and older with overweight and obesity Smoking abstinence Body weight change Calories per day Liraglutide (escalating doses of 0.6–3.0 mg weekly) or placebo in addition to smoking cessation counseling 32 weeks Study completed, results not yet published
NCT05530577 Treatment-seeking smokers 21–65 y/o with at least moderate nicotine dependence Nicotine self-administration Reinstatement of nicotine seeking Daily cigarette smoking Craving for and subjective responses to smoking Body weight change HbA1c levels Semaglutide (escalating doses of 0.25–1.0 mg weekly) 10 weeks Currently recruiting
NCT05610800 Treatment-seeking smokers 18–75 y/o with prediabetes and/or overweight Smoking abstinence Body weight change Neural responses to visual stimuli Extended-release exenatide (2 mg weekly) or placebo in addition to smoking cessation counseling and NRT (de-escalating doses of 21–7 mg/daily) 14 weeks Currently recruiting
NCT06173778 Treatment-seeking smokers 18–75 y/o with prediabetes and/or overweight Body weight change Body fat mass change Waist circumference change Semaglutide (escalating doses of 0.24–2.4 mg weekly) in addition to smoking cessation counseling and NRT (de-escalating doses of 21–7 mg/daily) 28 weeks Not yet recruiting

y/o = years old; NRT = nicotine replacement therapy.